HIV Infections Clinical Trial
— WISHOfficial title:
Improving the Reach and Effectiveness of Smoking Cessation Services Targeted to Veterans Living With HIV
This project will compare the effectiveness of an HIV-specific comprehensive wellness intervention designed to have broad appeal to smokers living with HIV to the effectiveness of standard care services that include referral to the National VA Quitline and SmokefreeVET texting program. Participants in both arms will have access to pharmacotherapy available through their Veterans Affairs (VA) healthcare providers.
Status | Recruiting |
Enrollment | 226 |
Est. completion date | August 31, 2025 |
Est. primary completion date | August 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - In care in the VA - HIV+ serostatus - Currently smoking 5+ cigarettes daily - Access to cell phone with text messaging capabilities - English speaking Exclusion Criteria: - Psychosis, dementia or significant cognitive impairment documented in the EHR - Documented or observed hearing or comprehension difficulties that would preclude participation in study telephone calls - Currently receiving cessation counseling or using an FDA approved treatment to quit smoking - Institutionalized/imprisoned - Pregnant |
Country | Name | City | State |
---|---|---|---|
United States | VA Puget Sound Health Care System Seattle Division | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Seattle Institute for Biomedical and Clinical Research | Fred Hutchinson Cancer Center, Kaiser Permanente, University of California, Davis, US Department of Veterans Affairs |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 7-day point-prevalence abstinence (PPA) | Smoking abstinence at 6-month follow-up by self-report and biochemically confirmed via saliva cotinine for a small selected group of individuals. Cotinine levels < 10 ng/ml and a self-report of 7 day PPA will be required to be coded a nonsmoker. | 6 months post-randomization | |
Primary | Any 24-hour intentional quit attempt | The primary outcome will be presence of an intentional quit attempt [yes/no] reported between randomization and 6 month follow-up. Quit attempts will be assessed at each follow-up. | 3 and 6 months postrandomization | |
Secondary | Floating prolonged abstinence | A proxy for sustained abstinence appropriate for evaluating a motivational intervention, in which the start point floats based on one's actual quit date rather than a pre-determined quit date | 3 and 6 months post-randomization | |
Secondary | 7-day self-report point-prevalence abstinence (PPA) | Self-report of abstinence from smoking, even a puff | 3 and 6 months post-randomization | |
Secondary | 30-day self-report point-prevalence abstinence (PPA) | Self-report of abstinence from smoking, even a puff | 3, 6, 12 months post-randomization | |
Secondary | Cigarettes smoked per day | Self-report; even a puff counts as smoking | 3 and 6 months post-randomization | |
Secondary | HIV-specific smoking knowledge | Items validated in a survey of Smokers Living with HIV conducted by the study team during a study titled "Smoking cessation-related information, motivation, and behavioral skills specific to HIV-infected smokers" (likert scale) | 3 and 6 months post-randomization | |
Secondary | Motivation to quit smoking | 1-10 likert scale | 3 and 6 months post-randomization | |
Secondary | Smoking cessation related to self-efficacy | 1-10 likert scale on domains (each) of quitting smoking, reducing smoking, managing cravings, and stimulus control | 3 and 6 months post-randomization | |
Secondary | Nicotine withdrawal symptom management (behavioral skills) | Self-report Minnesota Smoking Withdrawal Scale, Revised | 3 and 6 months post-randomization | |
Secondary | Cessation medication use and adherence (behavioral skills) | Self-report and health records (pharmacy) monitoring | 3 and 6 months post-randomization | |
Secondary | Absolute CD4 count | Lab value of CD4 ascertained via EHR | 6 and 12 months post-randomization | |
Secondary | VACS index 2.0 | Composite score based of various lab values ascertained via EHR | 6 and 12 months post-randomization | |
Secondary | Intentional quit attempt frequency and duration | Behavioral Risk Factor Surveillance System (BRFSS) | 3 and 6 months post-randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |